New results from a study presented at the ACC.17 Scientific Session demonstrated a better safety profile for Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim) vs. warfarin in atrial fibrillation patients undergoing catheter ablation. Findings were also published in the New England Journal of Medicine.
↧
Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation
↧